„Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome Case report

Main Article Content

Ana Martin-Garcia
Marta Alonso Fernandez de Gatta
María Diez-Campelo
Agustín C. Martín-García
Manuel Barreiro Pérez
Elena Diaz-Pelaez
Félix López Cadenas
Pedro L. Sanchez

Abstract

The most common non-hematological cause of death in patients with low-risk myelodysplastic syndrome (MDS) who receive chronic supportive transfusion therapy (STT) through red blood cells (RBC) is known to be related to cardiac events, especially, cardiac siderosis [1].
At the time patients develop symptoms secondary to cardiac toxicity, the disease reaches an advanced phase with a very high mortality rate. However, we report the case of an old female patient with severe acute heart failure (HF) and signs of elevated myocardial iron deposits by cardiac magnetic resonance, who experienced an unexpected and marked clinical improvement using a combination of intensive iron chelation therapy (ICT) and specific treatment for HF. She overcame the HF acute phase, recovered her systolic function and remained stable at mid-term of follow-up (18 months).

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Martin-Garcia A, Fernandez de Gatta MA, Diez-Campelo M, Martín-García AC, Barreiro Pérez M, Diaz-Pelaez E, López Cadenas F, Sanchez PL. „Iron Heart”: Reversible Cause of Dilated Cardiomyopathy Secondary to Cardiac Toxicity in Elderly Patient with Myelodysplastic Syndrome. OncoReview [Internet]. 2019Dec.31 [cited 2024Nov.22];9(4(36):88-1. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1084
Section
CARDIO-ONCOLOGY

References

1. Dayyani F, Conley AP, Strom SS et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010; 116: 2174-9.
2. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol 2010; 56: 1001-12.
3. Remacha AF, Arrizabalaga B, Villegas A et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol 2015; 94: 779-87.
4. Modell B, Khan M, Darlison M et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.
5. Tanner MA, He T, Westwood MA et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematologica 2006; 91: 1388-91.
6. Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program 2011; 2011: 443-50.